Education
Gandhi Medical College
Residencies
University of Arizona, Tucson - Hematology/Oncology
Internships
University of Arizona, Tucson - Hematology/Oncology
Fellowships
University of Arizona, Tucson - Hematology/Oncology
Clinical / Research Interests
Hormone Receptor Positive Breast Cancer
HER2 Positive Breast Cancer
Triple Negative Breast Cancer
Metastatic Breast Cancer
Biography

Pavani Chalasani, MD completed her medical school at Gandhi Medical College in India and completed her Internship, Residency and Fellowship in Hematology-Oncology at the University of Arizona, Tucson. Dr. Chalasani was a part of the University of Arizona Cancer Center (UACC) as a faculty member focusing on breast cancer where she was very active in clinical and translational research.  

Her key research interest is in the development of biomarkers- imaging, blood-based or tissue. She is the Principal Investigator on several investigator-initiated, industry-sponsored, and co-operative group protocols. She is the medical oncology study chair on S1706, a NCTN study for patients with inflammatory breast cancer.   She was awarded the prestigious NCI’s Clinical Cancer Investigator Team Leadership Award in 2020. She served as Program Director for Hematology-Oncology Fellowship program while at the UACC. She has received research funding from NIH/NCI, American Cancer Society, Better Than Ever and DOD. She was recruited to be Division Director for Hematology-Oncology at the George Washington University, George Washington Cancer Center (GWCC) and started in her new role 02/01/2023. She is also Co-Program Lead for Clinical Translational Oncology Program at GWCC.  

Clinical Trials

Primary Outcome Measures:

Determination of Overall survival (OS) [Time Frame: Until trial end, death, withdrawal of consent or lost to follow-up, assessed up to 60 months]
Determination of the Optimal Biological Dose (OBD) [Time Frame: Up to 15 months]
Frequency of adverse…

Primary Outcome Measure:
• To assess the safety and tolerability of tucatinib in combination with eribulin and trastuzumab in patients with unresectable or recurrent metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, and trastuzumab deruxtecan.
• Evaluate…

Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors